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Abstract
The management of viral hemorrhagic fevers (VHFs) has mainly focused on strict infection control measures, while
standard clinical interventions that are provided to patients with other life-threatening conditions are rarely offered
to patients with VHFs. Despite its complexity, a proper clinical case management of VHFs is neither futile nor is it
lacking in scientific rationale. Given that patient outcomes improve when treatment is started as soon as possible,
development and implementation of protocols to promptly identify and treat patients in the earliest phases of
diseases are urgently needed. Different pharmacological options have been proposed to manage patients and, as
for other life-threatening conditions, advanced life support has been proved effective to address multiorgan failure.
In addition, high throughput screening of small molecular libraries has emerged as a novel promising way to find
new candidates drugs for VHFs therapy and a relevant number of new molecules are currently under investigation.
Here we discuss the current knowledge about VHF clinical management to propose a way to step up the
approach to VHFs beyond the mere application of infection control measures.
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Background
The viral hemorrhagic fevers (VHFs) are a diverse group
of animal and human illnesses that are caused by four
distinct families of RNA viruses; these are: Arenaviridae,
Filoviridae, Bunyaviridae, and Flaviviridae. The severity
and clinical presentation of VHFs may significantly
change according to several different factors related to
the type of the causative agent, and the host epidemiolo-
gical and clinical features. In general, patients with VHFs
show fever and coagulation abnormalities that may pro-
gress towards disseminated intravascular coagulation,
multiorgan failure, shock and, eventually, death. VHFs
are always life-threatening diseases that may occur as iso-
lated case(s), such as imported case(s) from endemic
areas, or may cause devastating lethal outbreaks.
The management VHF cases has been mainly focused
on the strict application of infection control measures to
prevent transmission. However, high-level isolation and
containment procedures may hamper the implementation
of standard clinical interventions that would be offered to
critically ill patients infected with other life-threatening
pathogens. In developed countries, patients with septic
shock are admitted to intensive care units to receive high-
level primary medical and nursing care by a multidisciplin-
ary healthcare worker (HCW) team. These patients have
access to innovative medical drugs and to state-of-the-art
therapeutics (sometime off label or under compassionate
use protocols), and undergo any needed invasive interven-
tion to control the infection and/or manage any complica-
tions that may arise. In contrast, when VHF is suspected,
patients in similar conditions are usually confined to high
containment isolation units [1-3]. In particular, in develop-
ing countries where VHFs are most common, confinement
in combination with resource shortages may prevent
patients receiving any adequate basic nursing and medical
care. In fact, the recent Médecins Sans Frontières guide-
lines on the management of VHF patients in low-resource
settings, though recognizing the issue of patient care, dedi-
cate only a few lines to the clinical management issue [4].
Despite the practical difficulties of caring for VHF
patients, a proper clinical case management of VHFs is
neither futile nor does it lack of scientific rationale, as
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(whenever it is indicated) has been proved to improve
patient outcomes.
Here we discuss current knowledge about experimen-
tal prophylaxis and treatment of VHFs to propose a way
to step up the clinical approach to VHFs beyond the
mere application of infection control measures.
Discussion
The clinical perspective for VHF patients
Beside high-level standards of safety for HCWs, which
should be similar to those provided to bio-safety labora-
tory level 4 (BSL-4) personnel, a comprehensive proto-
col for clinical management of VHFs may not exclude
high standards of care for patients. In theory patient
care should include two main components. These are:
(1) specific antiviral treatment (which includes compas-
sionate or investigational use of therapeutic agents
based on data from phase 1/2/3 trials, non-randomized
studies or single case reports); and (2) advanced life sup-
port to prevent multiorgan failure.
In fact, in more routine circumstances (for example,
bacterial sepsis), patient outcome depends on both tar-
geted therapy (that is, antimicrobial therapy and modu-
lation of host response) and the support of vital organ
functions.
Based on clinical observations and on immunovirolo-
gical parameters, the course of severe VHFs can be
divided into three phases that require different clinical
approaches; that is, incubation, precoagulopathy and
coagulopathy [5]. The first phase begins with exposure
to the virus and persists throughout the presymptomatic
p e r i o d .A tt h i sl e v e l ,a c t i v e/passive immunization and
molecules with direct antiviral activity are the most
effective pharmacological option. The second phase
coincides with virus replication and the eventual vire-
mia. At this stage molecules with direct antiviral activity
can be still effective. The third and last phase is charac-
terized by the onset of coagulation abnormalities driven
by the dysregulation of the cytokine network (cytokine
storm) [5,6]. At this stage immune-modulating drugs
(for example, inhibitors of coagulation factors and/or
proinflammatory cytokines) are the only sensible option
although their actual efficacy is yet to be assessed.
Case definition
Animal models and clinical experience in humans indi-
cate that patient outcomes improve when treatment is
started as soon as possible. Therefore, a case definition
that can identify VHF patients in the early phases of dis-
eases is urgently needed.
The World Health Organization proposed in 1999 a
case definition for VHF to provide clinicians with a use-
ful tool for early VHF detection [7]. However, as shown
by Pittalis et al. [8] this case definition is too insensitive
both for case finding during outbreaks and for early
detection of suspected imported cases. In fact, the retro-
spective application of this case definition to 795 cases
of Ebola VHF and 169 cases of Marburg VHF resulted
in a sensitivity of 58.5% and 64.5%, respectively. This
indicates that a revision of current case definitions for
suspected VHF is necessary.
Since a universal case definition, valid in continuous
surveillance for imported cases and during ongoing out-
breaks, is hardly achievable, the best option is to have a
broad-based, relatively unspecific definition based on
both clinical (fever and other symptoms) and epidemio-
logical (contact with a case) criteria. This definition may
be promptly modified to include the specific characteris-
tics of the particular circumstances to be faced, such as
to confirm an imported cases in a developed country or
the rapid response to prevent the transmission during a
large ongoing outbreak in a low-resource setting.
Laboratory diagnostics
Currently there are no commercial kits for diagnosis of
VHFs, but a number of different diagnostics are avail-
able at specialized laboratories.
Nowadays, early diagnosis is mainly based on direct
detection of viral antigens or RNA. In particular the
United States Army Medical Research Institute of Infec-
tious Diseases [9] and New York Columbia University
[10,11], have recently developed multiplex PCR assays
for specific detection of multiple VHFs. Although field
data are limited (available only for Lassa), these systems
have been evaluated for the detection of a consistent
number of different agents form viral cultures, such as
Ebola, Marburg, Lassa, Machupo, Junin, Sabia, Guanar-
ito, Andes and Sin Nombre.
A further step to improve the molecular diagnosis of
VHFs would be attained by developing assays using
non-invasive sampling, which may be easier to obtain
than blood/serum during outbreaks. Molecular assays
using saliva or urine have been developed for dengue
[12], Crimean-Congo hemorrhagic fever (CCHF) [13],
Ebola [14] and there is evidence that a similar approach
may be undertaken for yellow fever [15], Marburg [16]
and Hantan [17] virus infections. However, it should be
noted that blood/serum is the preferable diagnostic spe-
cimen for most VHFs.
Given the physiological kinetics of humoral response
and the fact that VHFs are characterized by impairment
of the antigen-presenting cell functions, antibody titers
tend to be low at least in the earlier phases of diseases
[6]. Therefore serology is usually not the primary diag-
nostic option in acute phase but can be particularly use-
ful to confirm the diseases etiology in convalescent
patients.
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vant obstacles to the introduction of advanced diagnos-
tics in low-income settings. However the experience of
the 2005 Marburg outbreak in Angola [16] represented
a model of how to face shortages of personnel and facil-
ities even during outbreaks. On this occasion a mobile
laboratory unit was deployed to provide quantitative
real-time PCR assays with results available within 4 h
since receiving a sample. The facility operated over a
period of 88 days and tested 620 specimens from 388
individuals. It was possible to perform advanced diag-
nostics on different types of samples (including blood,
oral swabs and milk from child-bearing women). The
high concordance of test results from the mobile labora-
tory and those from the reference laboratory emphasizes
that advanced field laboratory capacity should be made
an essential part of future outbreak responses, as it is a
relevant support tool for patient management and epi-
demiological surveillance.
State-of-the-art of VHF treatment
Table 1 summarizes the main clinical and epidemiologi-
cal features of different VHFs agents with specific
recommended interventions to undertake.
Active vaccination for post-exposure treatment
Active vaccination with a recombinant vesicular stomatitis
virus (rVSV) expressing either the Zaire or Sudan ebola-
virus glycoprotein 30 minutes after lethal challenge has
shown 50% and 100% efficacy, respectively, in post-expo-
sure treatment of rhesus macaques [18,19]. Similar results
were obtained for a rVSV expressing the Marburg virus
glycoprotein (strain Musoke) with five out of six and two
out of six monkeys protected when the vaccine was given
even 24 h or 48 h after lethal challenge, respectively [20].
This approach could be very useful in the scenario of an
accidental exposure of a laboratory worker or HCW [21].
Passive immune protection
Specific antibodies against different VHF agents are typi-
cally present 5 to 9 days after the onset of illness, and
patients who die do not usually develop a measurable
antibody response [22,23]. This finding encourages the
therapeutic use of antibodies derived from recovered
patients or animals. In fact, the potential benefits of
immunoglobulin therapy were shown for treatments
based on hyperimmune serum prepared from the blood
of patients who recovered from CCHF or obtained by
immunizing horses [24].
Table 1 Treatment options for viral hemorrhagic fevers
Virus Family Incubation Virulence Communicability Isolation Treatment option(s)
Ebola Filoviridae 2 to 21 days High Yes Yes Post-exposure vaccination (rVSV);
rNAPc2; siRNA
Marburg Filoviridae 2 to 21 days High Yes Yes Post-exposure vaccination (rVSV)
Lassa Arenaviridae 6 to 21 days Moderate Yes Yes Ribavirin
Lujo Arenaviridae 6 to 21 days High Yes Yes Ribavirin
Junin Arenaviridae 6 to 21 days Moderate Yes Yes Passive immune therapy
Machupo Arenaviridae 6 to 21 days Moderate Yes Yes Passive immune therapy
Sabia Arenaviridae 6 to 21 days Moderate Unknown Yes
Guanarito Arenaviridae 6 to 21 days Moderate Unknown Yes
Chapare Arenaviridae 6 to 21 days Unknown Unknown Yes
Nipah Paramyxoviridae 4 to 18 days High Potential
a Yes Passive immune therapy
Hendra Paramyxoviridae 4 to 18 days High Unknown Yes Passive immune therapy
CCHF Bunyaviridae 3 to 7 days Moderate Yes Yes Ribavirin
Rift Valley fever Bunyaviridae 2 to 14 days Low to
moderate
No No Ribavirin
Hantan, Seoul, and so on Bunyaviridae Days to
months
Low to
moderate
No No Ribavirinn, hemodialysis
Sin Nombre, Andes, and
so on
Bunyaviridae Days to
months
Moderate No
b No
b ECMO
Yellow fever Flaviviridae 3 to 6 days Moderate No No
Dengue Flaviviridae 3 to 14 days Low No No
RSSE Flaviviridae 7 to 14 days Moderate No No
Omsk/KFD/AHF Flaviviridae 3 to 8 days Moderate Unknown Yes
aHuman-to-human transmission has been reported from outbreaks in Bangladesh.
bAndes virus has been reported to be transmissible from human to human; isolation may be indicated.
AHFV = Alkhurma hemorrhagic fever; CCHF = Crimean-Congo hemorrhagic fever; ECMO = extracorporeal membrane oxygenation; KFD = Kyasanur Forest disease;
RSSE = Russian spring-summer encephalitis; rVSV = recombinant vesicular stomatitis virus; siRNA = small interfering RNA molecule.
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adequate doses of specific neutralizing antibodies is the
current recommended treatment for Junín virus VHF;
this intervention has been proved to be effective in
improving clinical course of diseases and reducing mor-
tality to less than 1% [25].
Bulgarian investigators reported the prompt recovery
of seven severely ill patients treated with two specific
immunoglobulin preparations for intramuscular and
intravenous use, obtained from the plasma of CCHF
survivors boosted with one dose of CCHF vaccine [26].
Similarly, seven out of eight patients who were infected
during an outbreak in 1995 promptly recovered after
transfusions of convalescent-phase blood from other
subjects who had recovered from ZaireEbola virus infec-
tion [27]. In contrast, some non-human primate models
for passive immune therapy, in particular for filovirus
infections, are less encouraging. In fact, monkeys chal-
lenged with Ebola virus and eventually transfused with
convalescent phase blood achieved high antibody titers
but all succumbed to Ebola infection as quickly as con-
trol animals [28].
Besides conflicting results between empirical interven-
tions and animal models for some VHFs, several issues
should be considered when applying plasma therapy.
Firstly, plasma therapy is relatively inefficient when
initiated after 8 days of illness [25]. Secondly, a late self-
limiting neurological syndrome has been observed in the
10% of patients who received convalescent plasma for
Junín virus VHF. Thirdly, non-neutralizing crossreactive
antibodies may potently exacerbate the disease in several
conditions, such as Dengue and Marburg infections
[29,30]. Fourthly, there is an inherent risk of transfu-
sion-borne diseases. Fifthly, maintaining adequate stocks
of plasma may be unfeasible. Finally, the neutralizing
titers may decrease over time and plasma stocks must
be periodically assessed prior to use.
Antisense oligonucleotides
Gene-silencing treatment using small interfering RNAs
(siRNA) has given good results both in guinea pigs [31]
and non-human primate Ebola infection models [32]. In
one experiment nine monkeys were challenged with
Ebola virus, and subsequently three animals were treated
with four doses of intravenous siRNA (at 30 minutes,
a n dd a y s1 ,3 ,a n d5p o s te x p o s u r e ) ,f o u ra n i m a l sw i t h
seven doses of intravenous siRNA (30 minutes and days
1 to 6 post exposure), and two animals were left
untreated. Two of three monkeys who had received four
post-exposure doses and all of those who had received
seven post-exposure doses survived, while both controls
monkeys died. This data provide evidence that RNA
interference may be an effective post-exposure treat-
ment strategy for humans infected with Ebola virus and,
perhaps, other VHF agents. Unfortunately, production
and cost issues significantly limit the use of this
approach at present.
Antivirals
Ribavirin is an antiviral drug currently recommended for
prophylaxis and treatment of arenaviruses and bunya-
viruses [33], in particular ribavirin has been used to
treat patients with Lassa fever for more than 25 years
[34,35]. In addition, a randomized double-blind placebo-
controlled trial including 242 patients with serologically
confirmed Hantan virus in the People’s Republic of
China found a sevenfold decreased mortality among
ribavirin-treated patients [36]; however, other studies
d i dn o tc o n f i r mt h e s er e s u l t s. Ribavirin was also found
to be effective against CCHF virus in vitro [37], but dis-
cordant results have been reported from treatment of
CCHF patients in Iran and Turkey [38,39].
Pyrazinecarboxamide compounds, such as T-705 (favi-
piravir), T-1105 and T-1106, are being investigated in
vitro and in vivo as candidate antiviral drugs for differ-
ent VHFs. These compounds have shown good activity
in animal models for arenaviruses (Junin virus), bunya-
viruses, Rift Valley Fever virus (RVF), West Nile virus,
and yellow fever virus [40].
FGI-106 is a new molecule that has shown broad-
spectrum antiviral activity. FGI-106 showed potent in
vitro activity against several lethal pathogens such as,
Ebola, RVF and Dengue viruses. In addition in a mouse
model of Ebola virus infection, FGI-106 was found to
protect animals from lethal challenge [41].
High-throughput screening (HTS) of small molecular
libraries, has recently emerged as a novel promising way
to find new candidates molecules for VHF therapy [42].
An automated HTS system, integrated with optical
microscopy, has been implemented to assess antiviral
activity and potential cytotoxicity for chemical com-
pounds against Dengue virus. This system assessed the
antiviral activity against Dengue virus type 2 and cyto-
toxicity on human HEK293 of 5,632 molecules. In this
way, 73 molecules were found to have both strong anti-
viral activity and no cytotoxicity and were identify as
potential candidates for further in vivo research [43].
HTS technology has also been used on BSL-4 patho-
gens, such as filoviruses and arenaviruses, by the imple-
mentation of replication-incompetent virus pseudotypes.
The research for arenaviruses discovered potent entry
inhibitors against Lassa virus, Junin virus, Sabia virus,
Machupo virus and Guaranito virus [42,44]. As well
entry inhibitors for filovirus were also find by HTS
approach. In particular a benzodiazepine derivative was
identified with a 50% inhibitory concentration of 10 μM
and 12 μM, for Ebola and Marburg viruses, respectively
[45]. HTS has also been used to investigate molecules
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aminopyrrolidine compound (PF-429242) that acts as a
potent SKI-1/S1P inhibitor (a cellular protease which is
essential for the processing of viral envelop protein pre-
cursors) has recently been discovered. This compound
has high stability, low toxicity and pharmacokinetic
properties that made it an interesting drug candidate in
the context of arenavirus [46,47] and CCHF virus [48]
infections.
Immune-modulating drugs
Several indirect lines of evidence suggest that modulat-
ing coagulation factors and/or cytokines activity may
represent a new promising field of investigation for VHF
therapy.
Firstly, studies on rhesus macaques demonstrate that
therapy with recombinant inhibitor of factor VIIa/tissue
factor and activated protein C are associated with signif-
icant increased survival after experimental infection with
Zaire Ebola virus [49,50]. In addition recombinant
human activated protein C showed good efficacy against
severe malaria infections with multisystem organ failure
[51]. Souza et al. [52] have also reported that activation
of platelet-activating factor receptor (PAFR) could
account for the major systemic manifestations of dengue
infection. Activation of PAFR on endothelial cells and
leukocytes induces increased vascular permeability,
hypotension, and productiono fc y t o k i n e s .I nam o u s e
dengue model, treatment with an orally active PAFR
antagonist (modipafant) prevented both the hypotension
and the increase of vascular permeability, resulting in
decreased lethality even when started 5 days after virus
inoculation. This suggests that activated protein C,
recombinant inhibitor of factor VIIa/tissue factor and
modipafant might be considered in future clinical trials
f o rs e v e r ed e n g u ea n d / o rE b o l ai n f e c t i o n si np a t i e n t s
with shock not responsive to standard support
treatments.
Secondly, preliminary studies have proposed a key role
for macrophage migration inhibitory factor (MIF) in
dengue pathogenesis [53]. MIF is a product of activated
macrophages, which sustains macrophage survival and
carries out its activity by suppressing p53-dependent
apoptosis. Compared to wild-type mice, dengue-infected
MIF -/- mice show decreased macrophage viability,
decreased proinflammatory function and increased
apoptosis, which results in lower viral load, less severe
clinical manifestations and a significant delay in lethality.
As patients with dengue hemorrhagic fever show ele-
vated plasma concentrations of MIF [54], it is possible
that neutralizing MIF activity may have a role in the
treatment of severe dengue in humans.
Finally it was shown that transgenic mice expressing
very high levels of human mannose-binding lectin
concentrations (a C-type lectin that recognizes hexose
sugars and acts as a first-line host defense against a
wide range of viral pathogens) are more resistant than
wild-type mice to fatal Ebola infections [55], this sug-
gests that modulation of mannose-binding lectin activity
may be an interesting field for further research.
Advanced life support
Proper intensive care should be provided to all patients
with VHF as for patients with other life-threatening
conditions unrelated to VHF (for example, bacterial sep-
sis) [6]. Several clinical experiences from developed
countries emphasize that an aggressive approach to
address multiorgan failure in patients with Hantavirus
VHF can be life saving. In particular an aggressive
approach including steroids, vasoactive, hemodialysis
and mechanical ventilation provided excellent outcomes
in three patients (34, 42 and 72 years old) with multior-
gan failure due to Puumala virus infection in Finland
[56] and Austria [57]. In addition, retrospective data
analysis of 38 subjects with severe Hantavirus cardiopul-
monary syndrome in the USA [58,59] showed that
initiation of extracorporeal membrane oxygenation to
address acute respiratory distress syndrome may drama-
tically reduce complications and improve the overall
survival. This confirms that invasive interventions, such
as extracorporeal membrane oxygenation to address
refractory hypoxemia [60] and hemodialysis to support
renal function, should be considered in patients with
VHFs.
Potential application in the future
There is currently a need to develop standardized clini-
cal protocols for VHF clinical case management that
integrate infection control measures with comprehensive
care for patients. In fact, although VHFs are most com-
mon in developing countries there are relevant strategic
reasons for investing in them worldwide, given the
increasing risk of exposure to VHF pathogens and the
possibility of importation of VHF cases into non-ende-
mic areas. In our opinion these protocols should be
developed in two steps.
Firstly, protocols should be developed and assessed in
developed countries on a limited number of patients.
For this, ‘centers of excellence’ should be established.
These centers should be able to provide: (1) safe, secure,
high-quality and appropriate care, with optimum infec-
tion containment and control procedures [2]; (2) a high
degree of expertise in critical care medicine and in the
management of tropical diseases; (3) high containment
(BSL-4) laboratories and skilled personnel to perform
differential diagnoses [61]; (4) validated models for the
management of such highly complex patients, including
the timely access to investigational and compassionate
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ground transportation system(s) to transfer patients
from the original location of exposure or the site where
they enter the public health system to the treatment
facility; and (6) established connections with interna-
tional organizations and disease-oriented networks of
infectious disease specialists and laboratories.
Drawing a simple scenario, the time between viral
exposure and symptoms onset might be used to trans-
port ‘highly suspect’ cases to a specialized center, fully
equipped with all necessary infection control measures
and clinical care expertise. At this center, assays for bio-
chemical markers and differential diagnosis could be
performed under adequate biocontainment measures
and interventions could be undertaken under strictly
controlled conditions. For example, the use of the
experimental VSV-based Marburg vaccine could be jus-
tified up to 40 hours after exposure based on efficacy
data in non-human primates and an expected slower
rate of VHF disease progressions in humans than in
macaques [62] and on the recent experience with the
VSV-based Ebola vaccine following an Ebola virus nee-
dle-stick exposure in Hamburg [21]. In case of severely
ill patients the transport should be carefully considered
and a clinicoepidemiological oriented risk assessment
should always be performed prior to making a decision
on transport. Such an approach can help to establish
and evaluate jointly shared and standardized protocols,
applicable across developed countries which will serve
as a model for other geographic regions, for the man-
agement of such rare but highly impacting infections.
The second, crucial step will consist in the translation
of these protocols into a format suitable to be imple-
mented in low-income settings. The main objectives will
be to facilitate access to high-level standards of care,
including experimental or compassionate use of thera-
peutics, to those who are in the greatest need. This kind
of international cooperation for improving management
of VHF patients is the most likely way forward for a bet-
ter understanding and care of these rare and challenging
clinical syndromes [63].
Support from national health authorities, major inter-
national public health partners and non-governmental
organization would greatly facilitate the sustainability of
the ‘excellence centers’ and the eventual production of
protocols to be implemented in developing countries.
Summary
Despite the obstacles to provide care for VHF patients,
and the limited, even disappointing clinical data on the
efficacy of clinically available drugs, we believe that pro-
viding access to promising new therapeutics, under
compassionate use protocols in carefully controlled set-
tings is not only ethically justified but urgently needed,
given the high lethality of these diseases and the impact
on national and international public health. In fact, even
though VHF outbreaks are rare and proper isolation and
high mortality during outbreaks will limit spread to
neighboring communities (the outbreak will ‘burn itself
out’), this cannot justify the current limited access to
the best available standards of care for the affected
patients and exposed HCWs.
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